Bridgebio Pharma is a biotechnology company focused on developing innovative therapies for genetic diseases and cancers
The company employs a collaborative approach, partnering with academic institutions and other organizations to advance its research and development efforts. Bridgebio aims to address significant unmet medical needs by leveraging its expertise in drug discovery and clinical development, with a portfolio that includes targeted therapies and programs designed to tackle fundamental genetic abnormalities. Through its commitment to scientific innovation, Bridgebio strives to improve patient outcomes and contribute to the future of precision medicine.
BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies.
BridgeBio Pharma shared new data showing that acoramidis reduced mortality and cardiovascular hospitalizations by 42% in its Phase 3 ATTRibute-CM study for ATTR-CM. FDA decision expected in November 2024.
BridgeBio Pharma released Phase 1/2 trial results for BBP-631, its gene therapy for congenital adrenal hyperplasia. The study demonstrated increased cortisol production and reductions in key biomarkers. BridgeBio plans to seek partners for further development.
In the very short term, I would say the further downside is likely but not for long. These are not ideal conditions, so either sit it out or make sure you take your profits early.
BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants who switched from placebo and tafamidis to acoramidis.
Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented at ESC Congress 2024. Regulatory submissions remain on track.
BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data shows sustained increases in height velocity and improved body proportionality with a good safety profile.
